Products

The compound tert-butyl 4-((2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate (CAS 1174020-63-3) possesses a sophisticated architecture built upon the diazabicyclo[3.2.1]octane core, a hallmark structure of next-generation non-β-lactam β-lactamase inhibitors. Its defining element is the seven-membered bicyclic scaffold featuring a unique N-O bond within the 6-(benzyloxy)-7-oxo arrangement, which is essential for the covalent inhibition of serine β-lactamases. The carbonyl group at the 7‑position serves as the reactive warhead that acylates the active site serine residue of the target enzyme. The benzyloxy substituent acts as a protecting group that is cleaved in vivo to unmask the key hydroxylamine functionality. A piperidine ring is appended to the bicyclic core via a carboxamide linkage, terminating in a tert-butyloxycarbonyl (Boc) protecting group that offers orthogonal deprotection selectivity. With its (2S,5R) stereochemistry precisely defined, this compound represents a late-stage intermediate in the synthesis of avibactam and relebactam.

(S)-3-Aminobutanenitrile hydrochloride is a chiral β-aminonitrile hydrochloride salt featuring a specific (S)-configured stereocenter at the third carbon position. The combination of an amino group (–NH₂) and a nitrile group (–CN) on a chiral scaffold, along with the hydrochloride salt form, provides excellent stability and water solubility, making it a crucial chiral building block in asymmetric synthesis and pharmaceutical development.

3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-2-(4-methoxyphenyl)-, (2R,3R,4S)-, (αS)-α-hydroxybenzeneacetate features a chiral 2,4-diaryl-substituted pyrrolidine-3-carboxylic acid core, a pharmacophore framework pioneered by Abbott Laboratories in the discovery of potent endothelin (ET) receptor antagonists such as A-127722 (atrasentan). The pyrrolidine ring bears three contiguous stereocenters at the 2R, 3R, and 4S positions, each essential for precise three-dimensional orientation required for high-affinity binding to the ETA receptor. The (4-methoxyphenyl) group at the 2-position and the (1,3-benzodioxol-5-yl) moiety at the 4-position contribute to lipophilic and electronic complementarity within the receptor’s binding pocket. The carboxylic acid at the 3-position serves as a hydrogen bond donor/acceptor for key active-site interactions. This compound is isolated as a salt with (αS)-α-hydroxybenzeneacetic acid (L-mandelic acid), a chiral resolving agent that stabilizes the enantiomerically pure (2R,3R,4S) configuration for downstream pharmacological applications.

3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-2-(4-methoxyphenyl)-, ethyl ester, (2α,3α,4α)- (CAS 173937-93-4) is a chirally complex 2,4-diarylpyrrolidine-3-carboxylic acid ethyl ester featuring three contiguous stereocenters in the (2α,3α,4α) configuration. This absolute stereochemical arrangement—specifically the trans,trans orientation of the two aryl substituents across the pyrrolidine ring—is the defining pharmacophoric signature of Abbott Laboratories’ seminal class of potent and selective endothelin A (ETA) receptor antagonists. The 4‑position bears a 1,3‑benzodioxole group, a metabolically stable isostere that enhances lipophilicity and contributes to optimized receptor occupancy. The 2‑position carries a 4‑methoxyphenyl ring, while the 3‑position features an ethyl carboxylate moiety that serves as a versatile handle for late‑stage functionalization via amidation or reduction. This precisely defined (2α,3α,4α) stereochemistry is not merely a structural nuance—it is the critical determinant of the high‑affinity ETA binding that enabled the discovery of the blockbuster drug Atrasentan (ABT-627).

1-Chloro-2-(chloromethyl)-3,5-dioxahexane, systematically named 1,3-dichloro-2-(methoxymethoxy)propane, is an acyclic, halogenated diether characterized by a central methine carbon flanked by two chloromethyl groups (–CH₂Cl) and a methoxymethyl (–OCH₂OCH₃) substituent. The combination of an electrophilic, α-haloalkyl ether structure with two labile chloromethyl moieties provides three distinct points for nucleophilic attack, positioning it as a uniquely versatile, three-pronged alkylating agent for constructing elaborate synthetic intermediates. This reactivity pattern makes it a valuable synthetic intermediate for the preparation of more complex molecules, particularly in pharmaceutical manufacturing and advanced organic synthesis.

Fumaric Acid Monoethyl Ester Zinc Salt (2:1) is an organometallic coordination compound formed by the reaction of the monoethyl ester of fumaric acid with zinc ions in a precise 2:1 molar ratio. The two monoethyl fumarate ligands coordinate to a central Zn²⁺ ion through their carboxylate groups, producing a discrete molecular salt whose bioactivity stems from its ability to release both the anti‑psoriatic monoethyl fumarate ligand and zinc ions in biological systems. This unique dual-release mechanism positions the compound as a promising candidate for pharmaceutical and biomedical applications.